Search Results - "Mahé, Julien"

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    Drugs associated with reversible cerebral vasoconstriction syndrome: A pharmacovigilance study in vigiBase by Favrelière, Sylvie, Mahé, Julien, Veyrac, Gwenaelle, Neau, Jean Philippe, Lafay-Chebassier, Claire, Pérault-Pochat, Marie Christine

    Published in Cephalalgia (01-08-2024)
    “…Data on drug-induced reversible cerebral vasoconstriction syndrome (RCVS) are scarce. We aimed to describe RCVS characteristics with drugs previously…”
    Get more information
    Journal Article
  2. 2

    Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase by Mahé, Julien, Campaigno, Emilie Patras, Chené, Anne‐Laure, Montastruc, Jean‐Louis, Despas, Fabien, Jolliet, Pascale

    Published in British journal of clinical pharmacology (01-10-2018)
    “…Aims To evaluate the risk of pleural disorders (PD) associated with 33 protein kinase (PK) inhibitors (PKIs) through a disproportionality analysis and to…”
    Get full text
    Journal Article
  3. 3

    Pharmacology and pharmacovigilance of protein kinase inhibitors by Khouri, Charles, Mahé, Julien, Caquelin, Laura, Locher, Clara, Despas, Fabien

    Published in Therapie (01-03-2022)
    “…Protein kinase inhibitors experienced their advent in the 2000s. Their market introduction made it possible to constitute a class of targeted therapies…”
    Get more information
    Journal Article
  4. 4

    Leukoencephalopathy with transient splenial lesions related to 5‐fluorouracil or capecitabine by Perrain, Valentine, Bihan, Kevin, Bompaire, Flavie, Houillier, Caroline, Jomier, Fanny, Leclercq, Delphine, Combret, Sandrine, Mahé, Julien, Ricard, Damien, Berzero, Giulia, Psimaras, Dimitri

    Published in European journal of neurology (01-07-2021)
    “…Background 5‐Fluorouracil (5‐FU) and its oral prodrug capecitabine have been rarely but consistently associated with acute central nervous system toxicity,…”
    Get full text
    Journal Article
  5. 5

    Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review by Bouquié, Régis, Deslandes, Guillaume, Mazaré, Hélène, Cogné, Marion, Mahé, Julien, Grégoire, Matthieu, Jolliet, Pascale

    Published in Fundamental & clinical pharmacology (01-10-2018)
    “…Cannabis is a plant that has been used for centuries to relieve a wide range of symptoms. Since the 1960s, interest in medical research into this plant has…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8

    Severe poisoning with naproxen causing coagulopathy by Lelièvre, Bénédicte, Drouillard, Isabelle, Thill, Chloé, Le Roux, Gaël, Bruneau, Chloé, Mahé, Julien, Deguigne, Marie, Boels, David

    Published in Basic & clinical pharmacology & toxicology (01-05-2020)
    “…Non‐steroidal anti‐inflammatory drugs (NSAIDs) are well known for their most frequent side effects (digestive, renal and metabolic disorders) but are lesser…”
    Get full text
    Journal Article
  9. 9

    Adverse Drug Reactions in Pediatric Emergency Medicine by Darnis, Domitille, Mahé, Julien, Vrignaud, Bénédicte, Guen, Christèle Gras-Le, Veyrac, Gwenaelle, Jolliet, Pascale

    Published in The Annals of pharmacotherapy (01-12-2015)
    “…Background: The pediatric population displays its own pharmacological characteristics, making children vulnerable to adverse drug reactions (ADRs). Objective:…”
    Get full text
    Journal Article
  10. 10

    Antibiotic prophylaxis for the prevention of infective endocarditis for dental procedures is not associated with fatal adverse drug reactions in France by Cloitre, A, Duval, X, Tubiana, S, Giraud, P, Veyrac, G, Nosbaum, A, Gouraud, A, Mahé, J, Lesclous, P

    “…One of the major reasons to stop antibiotic prophylaxis (AP) to prevent infective endocarditis (IE) in the United Kingdom but not in the rest of the world was…”
    Get full text
    Journal Article
  11. 11

    Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis by Mahe, Julien, Meurette, Aurélie, Moreau, Anne, Vercel, Caroline, Jolliet, Pascale

    Published in Drug design, development and therapy (01-01-2013)
    “…Interferon beta-1a is available as an immunomodulating agent for relapsing forms of multiple sclerosis. Common side effects include flu-like symptoms,…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14

    Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis by Brochard, J., Morio, F., Mahe, J., Le Pape, P., Guimard, T., Mahe, B., Leterrier, M., Morrier, M., Raffi, F., Boutoille, D.

    Published in Médecine et maladies infectieuses (01-11-2020)
    “…•Cryptococcus neoformans infections are increasingly reported in patients receiving ibrutinib.•Study of 19 cases and analysis from the international…”
    Get full text
    Journal Article